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Cognitive impairment is common in Parkinson’s disease (PD), but often not improved by dopaminergic treatment. New treatment
strategies targeting other neurotransmitter deficits are therefore of growing interest. Imaging the brain at rest (‘task-free’) provides the
opportunity to examine the impact of a candidate drug on many of the brain networks that underpin cognition, while minimizing task-
related performance confounds. We test this approach using atomoxetine, a selective noradrenaline reuptake inhibitor that modulates the
prefrontal cortical activity and can facilitate some executive functions and response inhibition. Thirty-three patients with idiopathic PD
underwent task-free fMRI. Patients were scanned twice in a double-blind, placebo-controlled crossover design, following either placebo or
40-mg oral atomoxetine. Seventy-six controls were scanned once without medication to provide normative data. Seed-based correlation
analyses were used to measure changes in functional connectivity, with the right inferior frontal gyrus (IFG) a critical region for executive
function. Patients on placebo had reduced connectivity relative to controls from right IFG to dorsal anterior cingulate cortex and to left IFG
and dorsolateral prefrontal cortex. Atomoxetine increased connectivity from the right IFG to the dorsal anterior cingulate. In addition, the
atomoxetine-induced change in connectivity from right IFG to dorsolateral prefrontal cortex was proportional to the change in verbal
fluency, a simple index of executive function. The results support the hypothesis that atomoxetine may restore prefrontal networks related
to executive functions. We suggest that task-free imaging can support translational pharmacological studies of new drug therapies and
provide evidence for engagement of the relevant neurocognitive systems.
Neuropsychopharmacology (2016) 41, 2171–2177; doi:10.1038/npp.2016.18; published online 2 March 2016
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INTRODUCTION
Parkinson’s disease (PD) impairs cognition, including executive
functions, attentional control, decision-making, verbal fluency,
and response inhibition. These deficits may be present soon
after diagnosis and impair quality of life despite dopaminergic
therapy (Watson and Leverenz, 2010; Yarnall et al, 2013). New
approaches are required to maintain or restore cognitive
function, in addition to the mainstay of dopaminergic therapy.
Dopaminergic therapy does not satisfactorily restore
executive functions in PD (Weintraub et al, 2006; Rowe
et al, 2008), due in part to deficits in non-dopaminergic
systems. For example, noradrenergic projections from the
locus coeruleus to the cortex are severely affected by PD
pathology (Braak et al, 2003). Loss of noradrenaline has
been implicated in diverse deficits in executive functions such
as inhibition, attention, working memory, cognitive flex-
ibility, and verbal fluency (Ye et al, 2015; Kehagia et al, 2014;
Vazey and Aston-Jones, 2012; Williams-Gray et al, 2007;
Robbins and Arnsten, 2009). Noradrenergic drugs therefore
provide a potential mechanism to restore cognitive functions
in selected patients (Kehagia et al, 2014; Ye et al, 2015).
Noradrenergic projections from the locus coeruleus reach
the inferior frontal gyrus (IFG), presupplementary motor
area (pre-SMA), dorsolateral prefrontal cortex, and anterior
cingulate cortex (Goldstein et al, 2011). These are critical
areas for executive function, inhibition, working memory,
and fluency (Gauthier et al, 2009). For example, the right
IFG and pre-SMA are important for response inhibition and
attentional processing (Rae et al, 2015; Sharp et al, 2010) and
are modulated by noradrenaline (Ye et al, 2015; Vazey
and Aston-Jones, 2012).
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The selective noradrenaline reuptake inhibitor atomox-
etine increases noradrenergic neurotransmission within the
prefrontal cortex (Bymaster et al, 2002). In preclinical
studies, atomoxetine improves attentional set-shifting
(Newman et al, 2008) and response inhibition (Robinson
et al, 2008). Atomoxetine also improves response inhibition
and increases right IFG activation during inhibition by
healthy humans (Chamberlain et al, 2009).
Preliminary trials of PD have shown that atomoxetine can
improve inhibition and attention in some patients (Kehagia
et al, 2014; Ye et al, 2015). Using task-based functional
magnetic resonance imaging (fMRI), Ye et al (2015, 2016)
showed that the behavioral effect of atomoxetine on inhibi-
tory control in Parkinson’s patients was related to enhanced
right IFG activity and stronger frontostriatal connectivity.
However, the majority of pharmacological imaging studies,
including Ye et al (2015, 2016), use task-based paradigms.
This approach has several potential disadvantages including
performance confounds, practice effects across sessions, and
the ambiguity arising from activation differences in the
context of very different performance by patients (Price and
Friston, 1999). They also require participant training and are
limited to the relatively narrow range of neural systems
related to the task.
There is an alternative approach, using task-free fMRI
(also known as resting-state fMRI). This minimizes training
demands, task-related confounds, and practice effects across
sessions. It also allows for inclusion of cognitively and
physically impaired patients. In the absence of a task, one
cannot study task-related activations but one can examine
changes in brain network connectivity.
We therefore used task-free fMRI to investigate the effect
of atomoxetine on brain function in patients with PD, using
a double-blinded, randomized placebo-controlled crossover
design. We measured functional connectivity of the right IFG
because of this region’s central role in executive function,
including inhibition and fluency, and in mediating the
behavioral benefits of atomoxetine (Levy and Wagner, 2011).
We used seed-based correlation methods to compare
functional connectivity of the right IFG, first contrasting
patients on placebo with controls (between-group design)
and then contrasting patients on placebo to patients on
atomoxetine (within-group design). Individual differences
were accommodated using covariates of age, drug plasma
concentration, disease severity, and the change in out-of-
scanner cognitive performance under atomoxetine vs placebo.
We tested the specific hypotheses that (i) PD reduces
functional connectivity of the right IFG with other regions
implicated in executive function including the pre-SMA,
dorsolateral prefrontal, and anterior cingulate cortex; and
(ii) atomoxetine restores the functional connectivity of the
right IFG to these regions.
MATERIALS AND METHODS
Participants
Thirty-three people with idiopathic PD were recruited from
the Cambridge University PD Research Clinic using UK PD
Society Brain Bank criteria. Subsets of these patients have
been included in previous studies reporting data sets from
functional tasks (Ye et al, 2015, 2016). Seventy-six healthy
age- and sex-matched controls were recruited from the
Medical Research Council’s Cognition and Brain Sciences
Unit volunteer panel and healthy volunteers registered with
the Cambridge University PD Research Clinic, at the John van
Geest Centre for Brain Repair. Inclusion criteria were (1) age
between 45 and 80 years; (2) non-demented, with Mini-Mental
State Examination (MMSE)426/30, noting that this does not
exclude mild cognitive impairment; and (3) no significant
current depression. None of the patients reported symptoms
or behaviors of impulse control disorders at interview.
Participants underwent assessment with the MMSE, digit
span forward and backward, category and letter fluency
(Rittman et al, 2013) plus the revised Beck Depression
Inventory. Patients were assessed with the Unified PD Rating
Scale motor subscale III at the start of each session. All
participants provided written informed consent. The study
was approved by the local research ethics committee and was
exempted from clinical trials status by the United Kingdom
Medicines for Human use Regulatory Agency.
We anticipated that any potential future use of noradre-
nergic drugs for cognition would be adjunctive to dopami-
nergic medication, not a replacement. Therefore, all patients
were tested on their regular medication, to assess the effect of
atomoxetine in the context of clinically optimized standard
dopaminergic and/or cholinergic therapy. Levodopa equiva-
lent dose (LED) was calculated for each patient (Tomlinson
et al, 2010). Participant demographics and clinical char-
acteristics are summarized in Table 1.
Experimental Design
The study used a double-blinded placebo-controlled cross-
over design for patient treatment by atomoxetine and
placebo, randomized within successive blocks of six recruits
to maintain balanced groups. Each patient underwent two
separate sessions of cognitive and neurological assessments
and brain imaging, at least 6 days apart but at approximately
the same time of day on each session. At the start of each
session patients received a 40 mg oral dose of atomoxetine or
placebo. They were transferred to the MRI suite 2 h after the
drug administration to coincide with the peak plasma
concentration of atomoxetine (Sauer et al, 2005: unpublished
day-curve data in a separate group of 20 PD patients
confirms peak plasma levels between 120 and 180 min).
Control participants were scanned once without the drug to
provide normative data. The principal analysis is of the main
effect of drug treatment within PD, not a drug by group
interaction.
fMRI Data Acquisition and Preprocessing
Task-free functional imaging was performed at rest using a
TIM-Trio 3T Magnetic Resonance Imaging (MRI) scanner
(Siemens Medical Systems, Erlangen, Germany). A mini-
mum of 145 volumes was acquired using an echo-planar
imaging (EPI) sequence (repetition time (TR) 2000 ms, echo
time (TE) 30 ms, matrix= 64 × 64, in-plane resolution of
3 × 3mm, 32 slices of 3 mm thickness with a 0.75 mm
interslice gap, and a flip angle (FA) of 78°). Structural
Magnetization-Prepared Rapid Acquisition with Gradient
Echo (MPRAGE) scans (TR of 2300 ms, TE of 2.86 ms,
matrix= 192 × 192, in-plane resolution of 1.25 × 1.25 mm,
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144 slices of 1.25 mm thickness, inversion time of 900 ms and
FA of 9°) were also acquired during the same session.
We used a preprocessing pipeline optimized for older
subjects to take into account atrophy and subject’s head
movement in the scanner (Patel et al, 2014). The Diffeo-
morphic Anatomical Registration Through Exponentiated
Lie Algebra (DARTEL) algorithm (Ashburner, 2007) created
a study-specific template from MPRAGE images. Unified
six-tissue class segmentation was applied to structural images
and grey and white matter segments from all participants
were warped together iteratively over six steps to create a
study-specific template, which was then affine transformed
to MNI space.
We used a customized version of the brainwavelet toolbox
(www.brainwavelet.org) to perform preprocessing of func-
tional images. The first five volumes were removed and the
mean EPI image was coregistered to the T1 image and then
transformed to MNI space using the flow fields generated
during the DARTEL processing. Subsequent processing of
the functional time series included slice-timing correction to
correct for acquisition delay, combined regression of
cerebrospinal fluid (CSF) signal and motion derivatives,
high-pass band filter (0.01 Hz), and wavelet despiking (Patel
et al, 2014). Spatial smoothing was applied with an 8mm
isotropic Gaussian kernel.
In-scanner head movements can produce spurious corre-
lations in task-free fMRI data (Power et al, 2012). In the
current study, we combined several approaches to minimize
these motion-related effects on the blood oxygen level-
dependent (BOLD) signal. First, the wavelet despiking
toolbox was used during preprocessing: movements related
to non-stationary events in each voxel were identified and
despiked from the time course. Second, six parameters of
head motion were used as regressors during seed-correlation
analysis (see Functional connectivity analysis section below).
Third, four participants were excluded (one control, three
patients) based on a high average root mean-squared (RMS)
displacement computed from the translation parameters of
head motion: average RMS displacement over 2 SDs from the
mean and/or 2 SDs from the mean difference between
placebo and atomoxetine sessions.
We also assessed motion between imaging sessions within
the patient group. The average RMS displacement did not
differ significantly between placebo and atomoxetine ses-
sions (p= 0.79, t= 0.26). It is therefore unlikely that drug
effects on measures of functional connectivity were driven by
cross-session differences in head movement.
Functional Connectivity Analysis
To investigate the effect of disease and drug on functional
connectivity between brain regions, seed-to-voxel connectiv-
ity maps were created for each subject per condition.
Statistical Parametric Mapping software (SPM12, http://
www.fil.ion.ucl.ac.uk/spm) was used to perform seed-based
correlation functional connectivity analysis. A seed was
created for the right IFG as a 5 mm radius sphere (MNI
coordinates: 56, 16, and 12). The coordinates for this seed
region were derived from a separate data set acquired by Ye
et al (2015). The time series of the seed region was extracted
from the rs-fMRI data for each individual. Signals deriving
from the CSF and white matter (WM) were extracted using
template masks.
The mean time series of the seed region was then
correlated with the time series of each voxel in the whole
brain in a multiple regression model. Head motion
parameters as well as WM and CSF signals were included
as nuisance regressors to minimize the influence of these
non-neuronal signals on correlations with the IFG seed
region. The voxel-wise parameter estimates of linear
regression were used to create correlation maps for each
subject and for each session, which were then Fisher
z-transformed to correct the variance in the distribution of
correlation coefficients. Individual correlation maps were
used in a second-level general linear model to compare
functional connectivity of the right IFG between controls and
patients (on placebo) and to determine if the drug-enhanced
connectivity in patients on atomoxetine vs placebo. Two-
sample t-test maps were thresholded at po0.05 voxel-level
FWE-whole brain-corrected plus an exploratory analysis at
threshold po0.001 uncorrected.
Age, LED, drug plasma concentration, UPDRS-III, and the
change in neuropsychological performance (eg: fluency)
between atomoxetine and placebo sessions were included as
covariates to investigate the influence of individual differ-
ences on treatment response.
RESULTS
Participant Demographics
Data from 75 controls and 30 patients were used in the final
analysis. A summary of demographic and clinical measures
for controls and patients is reported in Table 1. Patients and
healthy controls were matched in terms of sex, age, and
education. PD subjects had lower MMSE and category
fluency scores compared with controls as expected.
Table 1 Participant Clinical and Demographic Characteristics
PD patients,
mean (SD)
Controls,
mean (SD)
Difference
(p-value)
Male:female 19 : 11 41 : 34 NS
Age (years) 67 (7.3) 67.1 (8.4) NS
Education (years) 14.2 (3.6) 14.8 (4.0) NS
MMSE 28.4 (1.7) 29.2 (1.1) 0.009
Category fluency 18.3 (5.5) 24.3 (6.2) 0.0001
Letter fluency 16.0 (4.4) 18.3 (5.7) NS
Digit span forward 7.0 (1.1) 7.3 (0.8) NS
Digit span backward 5.5 (1.2) 6.0 (1.3) NS
Disease duration
(years)
10.5 (4.4) — —
LED (mg per day) 870 (469) — —
UPDRS III ‘on’ 22.6 (6.8) — —
Atomoxetine plasma
concentration (ng/ml)
372.1 (167.4) — —
Abbreviations: LED, levodopa equivalent dose; MMSE, Mini-Mental State
Examination; NS, nonsignificant; PD, Parkinson’s disease; UPDRS III, the Unified
Parkinson’s disease rating scale motor subscale.
Groups are compared by unpaired t-test or χ2 test as appropriate (NS, p40.05
uncorrected). LED according to the formula of Tomlinson et al (2010).
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Right IFG Connectivity Between Controls and Patients
Comparing controls and patients on placebo revealed a
reduction in functional connectivity between the right IFG
and left IFG/dorsolateral prefrontal cortex as well as the left
cerebellum (Table 2 and Supplementary Figure S1). Regions
with reduced functional connectivity between the right IFG
at the exploratory threshold also included the dorsal anterior
cingulate and pre-SMA.
The Effect of Atomoxetine on Connectivity
Atomoxetine increased the functional connectivity between
the right IFG and dorsal anterior cingulate in PD patients
(po0.05 FWE-corrected, see Figure 1 and Table 2). The
dorsal anterior cingulate region with increased connectivity
with the right IFG was bilateral but asymmetrical, mainly on
the right side. Age, LED, drug plasma concentration, and
UPDRS-III did not significantly interact with the drug-
induced changes in connectivity.
There was an interaction between the effect of atomoxetine
on right IFG connectivity and category fluency during each
session. Specifically, patients with greater improvement in
their out-of-scanner category fluency immediately before
imaging (on atomoxetine relative to placebo) also demon-
strated greater increases in functional connectivity between
the right IFG and the left dorsolateral prefrontal cortex
(see Figure 2 and Table 2). There was no interaction
between drug plasma concentration, or any other covariate,
and the effect of atomoxetine on right IFG functional
connectivity.
DISCUSSION
We have shown that the selective noradrenergic reuptake
inhibitor atomoxetine increases the functional connectivity
between the right IFG and dorsal anterior cingulate cortex in
PD. These two regions form a critical network for executive
function, as evidenced by studies of task-based fMRI and
focal brain lesions, but their interaction was revealed in this
study by task-free fMRI. Atomoxetine also increased the
connectivity between the IFG and dorsolateral prefrontal
cortex, in proportion to the change in executive function
(indexed by verbal fluency). Previous task-based investiga-
tions have indicated noradrenergic enhancement of regional
activity and/or functional connectivity in the frontal lobe (Ye
et al, 2015; Cubillo et al, 2014; Chamberlain et al, 2009).
However, the ability to detect homologous modulations of
network connectivity in the resting state, without complex
tasks, opens up the use of fMRI to examine candidate
therapeutic strategies for cognitive enhancement with
reduced demands on timing constraints, training, and
performance confounds.
The reduction in task-free connectivity correlates with both
cognitive decline (Olde Dubbelink et al, 2014) and neuropsy-
chiatric complications (Yao et al, 2014) and abnormal connect-
ivity in PD has previously been reported (Kwak et al, 2010). In
our study, patients showed reduced connectivity compared
with healthy controls, between right IFG and the left IFG/
dorsolateral prefrontal cortex and dorsal anterior cingulate.
This accords with task-based studies of connectivity (Ye et al,
2015) and cognitive performance (Kehagia et al, 2014).
Taken together, these results support the neurobiological
model of noradrenergic regulation of executive functions
(Robbins and Arnsten, 2009), based on connectivity within
the medial and lateral prefrontal cortex. Atomoxetine
increased connectivity in this network, on a whole-group
level. These patient data are consistent with the preclinical
evidence. For example, enhanced noradrenergic neurotrans-
mission in the medial prefrontal cortex facilitates attentional
set-shifting performance in rats (Lapiz and Morilak, 2006),
whereas noradrenergic depletion impairs attention during
distracting conditions (Carli et al, 1983). Human imaging
studies also suggest that interactions between dorsal anterior
cingulate and right IFG support the executive function of
attentional control and inhibition. For example, they are
active during low-frequency events and error trials in choice
discrimination and response inhibition tasks (Braver et al,
2001); during performance monitoring and attentional
control (Botvinick et al, 2004); and in mediating response
strategies during inhibition via the pre-SMA and subcortical
structures (Sharp et al, 2010; Rae et al, 2015). The right IFG
was the only seed region included in the analysis, because of
task-based evidence of its involvement in executive dysfunc-
tion in PD and the neural mechanisms mediating the effect
of atomoxetine on cognition. However, it is possible that
atomoxetine also acts on other regions/networks and that
these are also relevant to the drugs’ cognitive benefits.
Given the integration of these regions within networks
regulating executive control, we speculate that atomoxetine
increased causal connections between them, known as
effective connectivity. However, a seed-based correlational
analysis does not provide direct evidence for effective
integration. The analysis of effective connectivity is facilitated
Table 2 Regions with Altered Connectivity with the Right Inferior
Frontal Gyrus Seed Region (Controls vs Patients and Atomoxetine
versus Placebo)
Coordinates Z-score Cluster size
(voxels)
Region with reduced connectivity in Parkinson’s disease
Left IFG/dorsolateral
prefrontal cortex
− 44 6 24 4.73 2669
Dorsal anterior cingulate 10 42 32 3.68* 48
Pre-SMA − 10 2 56 3.85* 217
Cerebellum − 10 − 54 − 8 5.22 3376
Region with increased connectivity on atomoxetine
Dorsal anterior cingulate
(main effect of drug)
12 34 18 4.73 416
Left dorsolateral prefrontal
cortex (drug interaction with
fluency)
− 50 20 34 3.98* 52
Abbreviations: DARTEL, Diffeomorphic Anatomical Registration Through
Exponentiated L; IFG, inferior frontal gyrus; MNI, Montreal Neurological Institute;
SMA, supplementary motor area.
Results are reported at whole brain family-wise error correction po0.05, or as
indicated by asterisk also at the exploratory threshold uncorrected po0.001.
Coordinates refer to the local peak in MNI space using a normalized
study-specific template (DARTEL).
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by strong anatomical priors and a task-based design, even
where stochastic dynamic causal models are used to study
task-free networks. It complements task-free methods that
were the focus of this study in view of their advantages in
terms of training, performance, and generalization to multiple
networks.
The partial restoration of noradrenergic function in PD
patients significantly modulated right IFG-left dorsolateral
prefrontal cortex connectivity as a function of atomoxetine-
induced changes in verbal fluency (category fluency task). In
other words, people showing the highest degree of improve-
ment in verbal fluency were also those who displayed the
greatest effect of atomoxetine on functional connectivity
within the prefrontal cortex. This result may explain the
heterogeneity of drug response in PD and suggests that task-
free fMRI might be used to develop biomarkers of individual
differences modulating response to pharmacological treat-
ments targeting cognition. Verbal fluency is impaired in PD
(Williams-Gray et al, 2007) and we hypothesized that this was
related to noradrenergic and structural deficits in prefrontal
networks (Goldstein et al, 2011; Rae et al, 2012). The
dorsolateral prefrontal cortex has also been implicated in
verbal fluency (Frith et al, 1991; Cuenod et al, 1995) and
noradrenergic transmission in this region is important for
other executive functions (Arnsten, 2011). In PD patients,
transcranial direct current stimulation of the dorsolateral
prefrontal cortex improved verbal fluency and enhanced
functional connectivity in verbal fluency networks (Pereira
et al, 2013). The right IFG is active during verbal fluency tasks
(Gaillard et al, 2000) and lesions to this region impair
category fluency (Biesbroek et al, 2015). Therefore, we suggest
that the functional connectivity between the right IFG and left
dorsolateral prefrontal cortex represents the integration of
executive strategies to support verbal category fluency.
There are several limitations to the current study. First, our
patients received a single dose of atomoxetine, in conjunc-
tion with the brain imaging. However, it is possible that
changes in functional connectivity following chronic drug
administration are different (Koda et al, 2010). Homeostatic
regulation, including for example, downregulation of nora-
drenergic receptors or synthesis, may ameliorate the effects
of the drug. In practice, this could be offset by dose
escalation, and in chronic therapy, patients with PD have
tolerated up to 100 mg daily (Marsh et al, 2009). Nonetheless,
future trials of clinical efficacy would need to assess longer-
Figure 1 Whole-brain seed-correlation comparing right inferior frontal gyrus (IFG) connectivity between placebo and atomoxetine sessions in patients with
Parkinson’s disease. (a) Right IFG seed region centered on 56, 16, and 12 (in blue). (b) Voxel-wise correlation map showing increased connectivity after
atomoxetine in patients, between right IFG and bilateral dorsal anterior cingulate (in orange) (atomoxetine4placebo; peak po0.05 family-wise error
(FWE)-corrected, z= 4.73). (c) Scatter plot showing the functional connectivity between right IFG and dorsal anterior cingulate peak during placebo and
atomoxetine sessions for each patient. ACC, anterior cingulate cortex.
Figure 2 Seed-correlation comparing connectivity between placebo and
atomoxetine sessions in patients with Parkinson’s disease. (a) The seed region
in right inferior frontal gyrus (IFG) (in blue). (b and c) Altered connectivity
between the right IFG and left dorsolateral prefrontal cortex (DLPFC) on
atomoxetine compared with placebo interacted with the change in category
fluency between these two sessions (in orange). Patients who improved on
the verbal fluency task while on atomoxetine also demonstrated increased
connectivity between these regions (p= 0.001 uncorrected).
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term treatment. Noradrenergic neurons in the LC exhibit
both tonic and phasic responses, and our data alone do not
discriminate the impact of atomoxetine on them. However,
preclinical data indicate that atomoxetine increases the
phasic-to-tonic firing ratio of the LC, thereby enhancing
noradrenaline release in the frontal cortex (Florin-Lechner
et al, 1996). We speculate that this effect mediates these
changes in functional connectivity. However, the neuro-
chemical mechanisms underlying the effect of atomoxetine
may not be exclusively related to its effect on noradrenergic
transmission. For example, atomoxetine may act via
noradrenergic systems alone or together with dopaminergic
transmission (Bymaster et al, 2002). Whereas animal studies
suggest that the benefits of atomoxetine on cognitive control
are mediated primarily by noradrenergic systems (Bari et al,
2009), interactions with dopamine cannot be excluded. For
example, connectivity between the lateral and medial
prefrontal cortex is partially dopamine dependent in the
context of motor control (Rowe et al, 2010), and cognitive
control is enhanced by drugs with joint dopaminergic and
noradrenergic effects such as methylphenidate (Moeller et al,
2014). It should also be noted that dopaminergic
drugs can modulate BOLD signal fluctuations (Kwak et al,
2012); however, this variable was kept constant in the
within-subject analysis comparing PD patients on and off
atomoxetine.
This study is not a clinical trial, and ultimately any new
therapy would be judged by its clinical impact, on cognition,
behavior, or motor control. However, we have demonstrated
that the modulation of functional connectivity in prefrontal
regions by atomoxetine in the task-free state is concordant
with understandings of networks relevant to executive
function as well as with changes in performance on
neuropsychological assessments performed outside the
scanner. This is in line with the correspondence between
brain networks identified in task-free and task-based
imaging (Smith et al, 2009). This technique also offers
insight into how individual differences influence treatment
response in terms of one or more brain networks, implicitly
demonstrating target engagement in the central nervous
system while minimizing the difficulties in learning or
executing challenging cognitive tasks. We suggest that this
technique is a useful contributor to understanding drug
effects on the brain, especially in early stages of translation,
but it would be a prelude to rather than a substitute for
clinical trials.
In conclusion, this study supports the noradrenergic
hypothesis for frontal lobe function and, indirectly, its role
in cognition. We demonstrate that task-free fMRI can be
used to examine therapies targeting cognitive systems and
investigate individual differences associated with treatment
response. Further work is needed for optimization of
potential noradrenergic therapies for PD, and to establish
the limits of this approach more generally in defining the
impact of drugs on neurocognitive systems.
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